Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 35Lymphoma, Follicular 14Lymphoma, Non-Hodgkin 9Waldenstrom Macroglobulinemia 8Lymphoma, B-Cell, Marginal Zone 7Lymphoma, Mantle-Cell 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma 4Leukemia, Myeloid, Acute 4Leukemia 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell 3Neoplasm Metastasis 2Multiple Myeloma 2Leukemia, Myelomonocytic, Chronic 2Hodgkin Disease 2Thrombocytosis 1Recurrence 1Prostatic Neoplasms 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoid Malignancies 1Leukemia, Prolymphocytic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1

Interventions

Docetaxel 277Prednisone 236enzalutamide 175Leuprolide 172Radiotherapy 164Abiraterone Acetate 153Magnetic Resonance Spectroscopy 147bicalutamide 137Goserelin 134Androgen Antagonists 111Radiosurgery 101acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 100apalutamide 78abiraterone 75gallium 68 PSMA-11 74Specimen Handling 67Gonadotropin-Releasing Hormone 58darolutamide 56Radiation 56Triptorelin Pamoate 53cabazitaxel 49Zoledronic Acid 49pembrolizumab 48Radiotherapy, Intensity-Modulated 47Flutamide 47Brachytherapy 47luprolide acetate gel depot 46Standard of Care 45Carboplatin 44Estramustine 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Prostatic Neoplasms × idelalisib × Clear all
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡